Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD19 CAR T cells (Institute of Hematology & Blood Diseases Hospital)
- Development stage
- Unknown
- Lead developer
- Institute of Hematology and Blood Diseases Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
CD19 CAR T cells (Institute of Hematology & Blood Diseases Hospital) is an autologous chimeric antigen receptor (CAR) T-cell therapy developed for the treatment of CD19-positive B-cell malignancies. The therapy is produced by genetically modifying a patient's own T cells using a lentiviral vector to express a second-generation CAR construct. This construct consists of an anti-CD19 single-chain variable fragment (scFv) for antigen recognition, a 4-1BB (CD137) costimulatory domain to enhance T-cell persistence and expansion, and a CD3ζ signaling domain to trigger T-cell activation upon binding to CD19-expressing cells. Primarily investigated by the Institute of Hematology & Blood Diseases Hospital (Chinese Academy of Medical Sciences), this therapy targets malignant B cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL) and B-cell acute lymphoblastic leukemia (B-ALL).
- Other names
- CD19 CAR-T cells (IHBDH)anti-CD19 scFv-4-1BB-CD3zeta CAR T cellsanti-CD-19 scFv-4-1BB-CD3zeta CAR T cellsanti-CD 19 scFv-4-1BB-CD3zeta CAR T cellsanti-CD19 scFv TCRζ:4-1BB CAR T cells
02
Targets
Beyond the preview
Go deeper on CD19 CAR T cells (Institute of Hematology & Blood Diseases Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD19 CAR T cells (Institute of Hematology & Blood Diseases Hospital).